The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
This transaction fundamentally strengthens Scinai's CDMO platform
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Iberdomide has the potential to be the first approved CELMoD agent
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
Subscribe To Our Newsletter & Stay Updated
